Sildenafil citrate 100 mg starting dose in men with erectile dysfunction in an international, double-blind, placebo-controlled study: effect on the sexual experience and reducing feelings of anxiety about the next intercourse attempt
In vitro studies suggest zafirlukast inhibits
- Sildenafil works by inhibiting phosphodiesterase type 5 enzyme.
- This inhibition increases cGMP levels in the body.
- Elevated cGMP leads to smooth muscle relaxation.
- It promotes vasodilation in the corpus cavernosum.
- This process facilitates an erection during sexual activity.
- The drug’s pharmacokinetics allow for rapid absorption.
- Food intake can influence absorption rate.
- It is effective in men of various ages.
CYP3A (weak) and CYP2C9 (moderate top potent).
The Key Differences Between Viagra and Sildenafil
Sildenafil is cleared predominantly by CYP3A (major route) and CYP2C9 (minor route). Use caution and monitor patients for potential sildenafil-related side effects. Verapamil: (Moderate) Monitor for an increase in sildenafil-related adverse reactions if coadministration with verapamil is necessary; consider a starting dose of 25 mg of sildenafil when prescribed for erectile dysfunction. PDE5 inhibitors, including sildenafil, may potentiate the hypotensive effects of vericiguat. Vigabatrin: (Major) Vigabatrin should not be used with phosphodiesterase inhibitors, which is associated with serious ophthalmic effects (e.g., retinopathy or glaucoma) unless the benefit of treatment clearly outweighs the risks. LiQrev Oral Susp: 1mL, 10mgRevatio/Sildenafil/Sildenafil
- Sildenafil citrate is a medication used primarily to treat erectile dysfunction.
- It belongs to the class of drugs called phosphodiesterase type 5 inhibitors.
- Sildenafil was originally developed to treat angina and hypertension.
- The drug works by increasing blood flow to the penis during stimulation.
- It is commonly sold under the brand name Viagra.
- Sildenafil is available by prescription and as generics.
- The typical dose is 50 mg taken about an hour before activity.
- Common side effects include headaches, flushing, and nasal congestion.
Citrate Intravenous Inj Sol: 0.8mg,
- Sildenafil is available in various dosages: 25 mg, 50 mg, 100 mg.
- Starting dose depends on individual health and response.
- Dose adjustments should be done under medical supervision.
- Overuse may lead to increased side effects.
- Missing a dose is generally safe; do not double up.
- The drug may be taken with or without food.
- It’s generally recommended to avoid heavy meals before taking.
- Always follow your healthcare provider’s guidance.
1mLRevatio/Sildenafil/Sildenafil Citrate Oral Pwd F/Recon:
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra Soft Tabs | 100mg | 180 + 8 Pills | 425.45€ 405.19€ | |
| Viagra Generic | 50mg | 10 Pills | 26.87€ 25.59€ | |
| Viagra Generic | 100mg | 10 Pills | 28.91€ 27.53€ | |
| Viagra Generic | 25mg | 60 + 4 Pills | 71.99€ 68.56€ | |
| Kamagra Soft Tabs | 100mg | 60 + 4 Pills | 180.59€ 171.99€ | |
| Kamagra | 100mg | 84 + 6 Pills | 264.44€ 251.85€ | |
| Viagra Generic | 100mg | 270 + 10 Pills | 270.47€ 257.59€ | |
| Viagra Generic | 150mg | 120 + 8 Pills | 177.58€ 169.12€ | |
| Kamagra Polo | 100mg | 272 + 12 Pills | 622.94€ 593.28€ | |
| Viagra Generic | 150mg | 30 + 2 Pills | 72.32€ 68.88€ | |
| Viagra Generic | 100mg | 360 + 10 Pills | 330.21€ 314.49€ | |
| Viagra Generic | 200mg | 180 + 10 Pills | 277.56€ 264.34€ | |
| Viagra Generic | 25mg | 180 + 6 Pills | 154.93€ 147.55€ | |
| Kamagra | 100mg | 20 Pills | 86.09€ 81.99€ | |
| Viagra Generic | 200mg | 90 + 6 Pills | 170.79€ 162.66€ | |
| Viagra Generic | 50mg | 270 + 8 Pills | 198.48€ 189.03€ | |
| Viagra Generic | 100mg | 60 + 4 Pills | 96.36€ 91.77€ |
1mL, 10mgRevatio/Sildenafil/Sildenafil Citrate/Viagra Oral Tab:
How should I take sildenafil?
No significant effect on the pharmacokinetic parameters of tacrolimus were observed. Tamsulosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on tamsulosin therapy before initiating therapy with the lowest dose of sildenafil. Tazemetostat: (Moderate) Monitor for decreased efficacy of sildenafil if coadministration with tazemetostat is necessary as concurrent use may decrease sildenafil exposure. Sildenafil is a sensitive CYP3A4 substrate and tazemetostat is a weak CYP3A4 inducer. Telmisartan; Amlodipine: (Moderate) Monitor for additive hypotension if amlodipine is administered concurrently with sildenafil, as both agents act independently to reduce blood pressure.
Clinical monitoring
Telotristat Ethyl: (Moderate) Monitor for decreased efficacy of sildenafil if coadministration with telotristat is necessary as concurrent use may decrease sildenafil exposure. Terazosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on alpha-blocker therapy before initiating therapy with the lowest dose of sildenafil. Tezacaftor; Ivacaftor: (Moderate) Increased monitoring is recommended if ivacaftor is administered concurrently with CYP2C9 substrates, such as sildenafil. Tipranavir: (Major) Sildenafil is contraindicated for use with tipranavir when used for pulmonary arterial hypertension (PAH). Sildenafil is a sensitive CYP3A4 substrate; tipranavir is a strong CYP3A4 inhibitor.
What dose should be taken?
Trandolapril; Verapamil: (Moderate) Monitor for an increase in sildenafil-related adverse reactions if coadministration with verapamil is necessary; consider a starting dose of 25 mg of sildenafil when prescribed for erectile dysfunction. Tranylcypromine: (Moderate) Additive hypotensive effects may be seen when monoamine oxidase inhibitors (MAOIs) are combined with sildenafil. Tucatinib: (Major) Coadministration with tucatinib is not recommended in patients receiving sildenafil for pulmonary arterial hypertension (PAH). When sildenafil is used for erectile dysfunction, consider a starting dose of 25 mg for patients receiving tucatinib. Vemurafenib: (Moderate) Concomitant use of vemurafenib with sildenafil may increase sildenafil exposure. 20mg, 25mg, 50mg, 100mg 100 mg/day PO for erectile dysfunction;
Voir aussi
Concomitant administration of strong CYP3A4 inducers is expected to substantially decrease plasma concentrations of sildenafil. Riociguat: (Contraindicated) Use of riociguat and sildenafil is contraindicated due to the risk of hypotension. Discontinue riociguat at least 24 hours prior to sildenafil administration and do not administer within 24 hours of sildenafil. Monitor for signs and symptoms of hypotension during transition of therapy. PDE5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.
Pulmonary hypertension
Ritlecitinib: (Moderate) Monitor for an increase in sildenafil-related adverse reactions if coadministration with ritlecitinib is necessary; consider a starting dose of 25 mg of sildenafil when prescribed for erectile dysfunction. Ritonavir: (Major) Coadministration of ritonavir is contraindicated in patients receiving sildenafil for pulmonary arterial hypertension (PAH). Sapropterin: (Moderate) Sapropterin acts as a cofactor in the synthesis of nitric oxide and may cause vasorelaxation. Caution should be exercised when administering sapropterin in combination with drugs that affect nitric oxide-mediated vasorelaxation such as phosphodiesterase inhibitors. When given together these agents may produce an additive reduction in blood pressure.
Other Medical Problems
The combination of sapropterin and a phosphodiesterase (PDE5) inhibitor did not significantly reduce blood pressure when administered concomitantly in animal studies. The additive effect of these agents has not been studied in humans. Saquinavir: (Major) Sildenafil is contraindicated for use with saquinavir when used for pulmonary arterial hypertension (PAH). Coadministration of saquinavir increased the sildenafil AUC by about 3-fold in a drug interaction study. Silodosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on silodosin therapy before initiating therapy with the lowest dose of sildenafil. 240 mg/day PO or 30
| Parameter | Value | Description | Notes |
|---|---|---|---|
| Absorption | Rapid | Peak plasma levels in 30-120 mins | After oral administration |
| Bioavailability | 40% | Percentage of dose reaching systemic circulation | Subject to food effects |
| Half-life | 4 hours | Time for plasma concentration to reduce by half | --- |
| Metabolism | Liver (CYP3A4 enzymes) | Mainly via CYP3A4 and CYP2C9 | |
| Excretion | Feces and urine | 80% via feces, 13% via urine |
mg/day IV for pulmonary arterial hypertension.
Side Effects
Conversely, patients already receiving an optimized dose of sildenafil should be started on the lowest dose of silodosin; increases in the alpha-blocker dose should be done in a stepwise fashion. Other variables, such as intravascular volume depletion, concurrent antihypertensive therapy, or evidence of hemodynamic instability with alpha-blocker monotherapy, may affect the safety of concomitant use of sildenafil and silodosin. Sodium Phenylbutyrate; Taurursodiol: (Moderate) Monitor for decreased efficacy of sildenafil if coadministration with taurursodiol is necessary as concurrent use may decrease sildenafil exposure. Sotorasib: (Moderate) Monitor for decreased efficacy of sildenafil if coadministration with sotorasib is necessary as concurrent use may decrease sildenafil uk price sildenafil exposure. St.
Autres utilisations
John's Wort, Hypericum perforatum: (Moderate) Monitor for decreased efficacy of sildenafil if coadministration with St. John's Wort is necessary as concurrent use may decrease sildenafil exposure. Sildenafil is a sensitive CYP3A substrate and St. John's Wort is a strong CYP3A inducer. Stiripentol: (Moderate) Consider a dose adjustment of sildenafil when coadministered with stiripentol.
Raynaud's phenomenon
Coadministration may alter plasma concentrations of sildenafil resulting in an increased risk of adverse reactions and/or decreased efficacy. In vitro data predicts inhibition or induction of CYP3A4 by stiripentol potentially resulting in clinically significant interactions. Tacrolimus: (Moderate) Consider initiating sildenafil at a low dose (25 mg) in kidney transplant recipients receiving tacrolimus. In a study of renal transplant patients, coadministration of tacrolimus with a single 50 mg dose of sildenafil resulted in an increase in the AUC, Cmax, and half-life of sildenafil. Decreases in blood pressure were also observed. 100 mg/day PO for erectile dysfunction; 240 mg/day
- Sildenafil citrate’s patent expiration increased market competition.
- Generics help reduce treatment costs globally.
- Pharmaceutical companies conduct clinical trials regularly.
- Safety monitoring continues post-marketing.
- Adverse event reporting is essential for drug safety.
- Patients should only use approved formulations.
- Counterfeit sildenafil products are a concern.
- Purchase from reputable sources is advised.
PO or 30 mg/day IV for pulmonary arterial hypertension.
| Condition | Reason | Notes |
|---|---|---|
| Nitrate therapy in patients | Severe hypotension | Absolute contraindication |
| Severe hepatic impairment | Altered metabolism | Use with caution |
| Retinitis pigmentosa | Possible retinal toxicity | Consult ophthalmologist |
| Hypotension (<90/50 mmHg) | Risk of exacerbating low BP | Monitor blood pressure |